The estimated Net Worth of Cesar L Alvarez is at least $823 Thousand dollars as of 9 March 2024. Mr. Alvarez owns over 106,837 units of Precigen Inc stock worth over $510,440 and over the last 16 years he sold PGEN stock worth over $0. In addition, he makes $312,495 as Independent Director at Precigen Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Alvarez PGEN stock SEC Form 4 insiders trading
Cesar has made over 23 trades of the Precigen Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 106,837 units of PGEN stock worth $103,632 on 9 March 2024.
The largest trade he's ever made was exercising 106,837 units of Precigen Inc stock on 9 March 2024 worth over $103,632. On average, Cesar trades about 5,717 units every 63 days since 2009. As of 9 March 2024 he still owns at least 526,227 units of Precigen Inc stock.
You can see the complete history of Mr. Alvarez stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Cesar Alvarez biography
Cesar L. Alvarez serves as Independent Director of the Company. Mr. Alvarez has served as a Board member since 2008. Mr. Alvarez is the Senior Chairman of the international law firm of Greenberg Traurig, LLP. He previously served as the law firm’s Executive Chairman, and as its Chief Executive Officer from 1997 to 2012. During his tenure as Chief Executive Officer and Executive Chairman, Mr. Alvarez led the firm to become one of the top ten law firms in the United States by leading its growth from 325 lawyers in eight offices to approximately 1,850 attorneys and government professionals in more than 36 locations in the United States, Europe, Asia, and Latin America. Mr. Alvarez also serves as: Chairman of the board of directors of Mednax, Inc. (NYSE: MD), a provider of physician services, including newborn, maternal-fetal, pediatric subspecialties, and anesthesia care; Vice Chairman of the board of directors of Watsco, Inc. (NYSE: WSO), a distributor of air conditioning, heating and refrigeration equipment and related parts and supplies; and The St. Joe Company (NYSE: JOE), a real estate development company. Mr. Alvarez served on the board of directors of Fairholme Funds, Inc., a family of publicly traded focused investment funds from May 2008 to February 2020 and Sears Holding Corporation, a retail company, from January 2013 to May 2017. Mr. Alvarez holds a Bachelor of Science, a Masters of Business Administration, and a Juris Doctor from the University of Florida.
What is the salary of Cesar Alvarez?
As the Independent Director of Precigen Inc, the total compensation of Cesar Alvarez at Precigen Inc is $312,495. There are 10 executives at Precigen Inc getting paid more, with Randal Kirk having the highest compensation of $2,067,620.
How old is Cesar Alvarez?
Cesar Alvarez is 72, he's been the Independent Director of Precigen Inc since 2008. There are 2 older and 16 younger executives at Precigen Inc. The oldest executive at Precigen Inc is Robert Shapiro, 81, who is the Lead Independent Director.
Insiders trading at Precigen Inc
Over the last 5 years, insiders at Precigen Inc have traded over $44,216,787 worth of Precigen Inc stock and bought 52,689,457 units worth $114,197,137 . The most active insiders traders include Randal J Kirk, Trading S.A. Ares, and Helen Sabzevari. On average, Precigen Inc executives and independent directors trade stock every 9 days with the average trade being worth of $358,866. The most recent stock trade was executed by Randal J Kirk on 9 August 2024, trading 23,529,411 units of PGEN stock currently worth $19,999,999.
What does Precigen Inc do?
precigen, inc. discovers and develops the next generation of gene and cellular therapies in the united states. it also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. in addition, the company offers ultravector platform that incorporates advanced dna construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbil15, a gene that enhances functional characteristics of immune cells; sleeping beauty, a non-viral transposon/transposase system; attsite recombinases, which breaks and rejoins dna at specific sequences; adenoverse technology platform, a library of engineered adenovector serotypes; and l. lactis is a food-grade bacterium. additionally, it provides rheoswitch inducible gene switch that provides qua
What does Precigen Inc's logo look like?
Complete history of Mr. Alvarez stock trades at Pediatrix Medical Inc, St. Joe Co, and Precigen Inc
Precigen Inc executives and stock owners
Precigen Inc executives and other stock owners filed with the SEC include:
-
Randal Kirk,
Executive Chairman of the Board -
Dr. Helen Sabzevari MPH, Ph.D.,
Pres, CEO & Director -
Donald Lehr,
Chief Legal Officer -
Rick Sterling,
Chief Financial Officer -
Jeffrey Perez,
Senior Vice President - Intellectual Property Affairs -
Helen Sabzevari,
President, Chief Executive Officer, President - Precigen, Inc. -
Donald P. Lehr,
Chief Legal Officer & Corp. Sec. -
Jeffrey Thomas Perez,
Sr. VP of Intellectual Property Affairs -
Jeffrey Kindler,
Independent Director -
Robert Shapiro,
Lead Independent Director -
Cesar Alvarez,
Independent Director -
James Turley,
Independent Director -
Dean Mitchell,
Independent Director -
Fred Hassan,
Independent Director -
Vinita Gupta,
Independent Director -
Steven Frank,
Independent Director -
Marie Rossi,
VP of Communications -
Steven Harasym,
Head of Investor Relations -
James Vincent Lambert,
Interim Principal Accounting Officer -
Rutul R. Shah,
Head of Operations & Portfolio -
Harry Thomasian Jr.,
Chief Financial Officer -
Dr. Thomas D. Reed,
Founder & Chief Science Officer -
Randal J. Kirk,
Exec. Chairman -
Harry Jr. Thomasian,
Chief Financial Officer -
Nancy H Agee,
Director -
Rutul R Shah,
Chief Operating Officer -
D. Bradford Osborne,
VP, Finance and Accounting -
Trading S.A. Ares,
10% owner -
Phil Tennant,
Chief Commercial Officer